Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India.
Curr Pharm Biotechnol. 2024;25(5):599-622. doi: 10.2174/0113892010242028231002075512.
Colorectal cancer (CRC) is a complex and multifactorial disorder in middle-aged people. Several modern medicines are available for treating and preventing it. However, their therapeutic uses are limited due to drawbacks, such as gastric perforation, diarrhea, intestinal bleeding, abdominal cramps, hair loss, nausea, vomiting, weight loss, and adverse reactions. Hence, there is a continuous quest for safe and effective medicines to manage human health problems, like CRC. In this context, herbal medicines are considered an alternative disease control system. It has become popular in countries, like American, European, and Asian, due to its safety and effectiveness, which has been practiced for 1000 years. During the last few decades, herbal medicines have been widely explored through multidisciplinary fields for getting active compounds against human diseases. Several herbal bioactives, like curcumin, glycyrrhizin, paclitaxel, chlorogenic acid, gallic acid, catechin, berberine, ursolic acid, betulinic acid, chrysin, resveratrol, quercetin, etc., have been found to be effective against CRC. However, their pharmacological applications are limited due to low bioavailability and therapeutic efficacy apart from their several health benefits. An effective delivery system is required to increase their bioavailability and efficacy. Therefore, targeted novel drug delivery approaches are promising for improving these substances' solubility, bioavailability, and therapeutic effects. Novel carrier systems, such as liposomes, nanoparticles, micelles, microspheres, dendrimers, microbeads, and hydrogels, are promising for delivering poorly soluble drugs to the target site, i.e., the colon. Thus, the present review is focused on the pathophysiology, molecular pathways, and diagnostic and treatment approaches for CRC. Moreover, an emphasis has been laid especially on herbal bioactive-based novel delivery systems and their clinical updates.
结直肠癌(CRC)是一种复杂的多因素疾病,发生于中年人。有几种现代药物可用于治疗和预防CRC,但由于胃穿孔、腹泻、肠道出血、腹痛、脱发、恶心、呕吐、体重减轻和不良反应等缺点,其治疗用途有限。因此,人们一直在寻求安全有效的药物来治疗 CRC 等人类健康问题。在这种情况下,草药被认为是一种替代疾病控制系统。由于其安全性和有效性,草药在美洲、欧洲和亚洲等国家已经流行了 1000 年。在过去的几十年中,人们通过多学科领域广泛探索草药,以获取针对人类疾病的活性化合物。几种草药生物活性物质,如姜黄素、甘草酸、紫杉醇、绿原酸、没食子酸、儿茶素、黄连素、熊果酸、齐墩果酸、白杨素、白藜芦醇、槲皮素等,已被证明对 CRC 有效。然而,由于其生物利用度低和治疗效果不佳,除了具有多种健康益处外,它们的药理应用受到限制。需要有效的给药系统来提高它们的生物利用度和疗效。因此,靶向新型药物传递方法有望提高这些物质的溶解度、生物利用度和治疗效果。新型载体系统,如脂质体、纳米粒子、胶束、微球、树枝状大分子、微球和水凝胶,可将难溶性药物递送到靶部位,即结肠。因此,本综述重点介绍了 CRC 的病理生理学、分子途径以及诊断和治疗方法。此外,特别强调了基于草药生物活性的新型给药系统及其临床更新。
Crit Rev Ther Drug Carrier Syst. 2020
Clin Chim Acta. 2020-2-1
Adv Colloid Interface Sci. 2020-2-19
Curr Pharm Des. 2024
Drug Deliv Transl Res. 2020-4
ACS Pharmacol Transl Sci. 2024-3-19
Eur J Pharmacol. 2021-11-5
Evid Based Complement Alternat Med. 2021-6-4
Front Pharmacol. 2021-1-19
Anticancer Agents Med Chem. 2022